open access

Vol 87, No 7 (2016)
Research paper
Published online: 2016-07-29
Get Citation

The role of early determination of β-human chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy

Handan Çelik, Miğraci Tosun, Yüksel Işık, Bahattin Avcı
DOI: 10.5603/GP.2016.0030
·
Pubmed: 27504939
·
Ginekol Pol 2016;87(7):484-487.

open access

Vol 87, No 7 (2016)
ORIGINAL PAPERS Gynecology
Published online: 2016-07-29

Abstract

Objective: The aim of the study was to determine the importance of β-hCG level on day 4 following methotrexate (MTX) administration, and the difference between β-hCG levels assessed on day 0 and day 4 in predicting treatment success.

Material and methods: A total of 68 women with tubal pregnancy, treated with a single dose of MTX, were selected for this retrospective study.

Results: The success rate of single-dose MTX treatment in our clinic was 75% (51/68). Among 51 patients in whom MTX treatment was successful, 25 (36.8%) showed a decrease in β-hCG level of > 15% on days 0 and 4, and 44 (64.7%) showed a β-hCG level decrease of > 15% on days 4 and 7. For subjects with β-hCG decrease of > 15% on days 4 and 7, the standard error was 6.5%, and the area under the ROC curve was 81.7%, while the corresponding values for days 0 and 4 were 7.2% and 64%, respectively.

Conclusions: A decrease of > 15 % in β-hCG levels between days 0 and 4 does not seem to be a better predictor for success of single-dose MTX treatment for ectopic pregnancy than between days 4 and 7. A statistically significant difference was observed only in β-hCG levels on day 7 in both, successful and unsuccessful single-dose MTX groups.

Abstract

Objective: The aim of the study was to determine the importance of β-hCG level on day 4 following methotrexate (MTX) administration, and the difference between β-hCG levels assessed on day 0 and day 4 in predicting treatment success.

Material and methods: A total of 68 women with tubal pregnancy, treated with a single dose of MTX, were selected for this retrospective study.

Results: The success rate of single-dose MTX treatment in our clinic was 75% (51/68). Among 51 patients in whom MTX treatment was successful, 25 (36.8%) showed a decrease in β-hCG level of > 15% on days 0 and 4, and 44 (64.7%) showed a β-hCG level decrease of > 15% on days 4 and 7. For subjects with β-hCG decrease of > 15% on days 4 and 7, the standard error was 6.5%, and the area under the ROC curve was 81.7%, while the corresponding values for days 0 and 4 were 7.2% and 64%, respectively.

Conclusions: A decrease of > 15 % in β-hCG levels between days 0 and 4 does not seem to be a better predictor for success of single-dose MTX treatment for ectopic pregnancy than between days 4 and 7. A statistically significant difference was observed only in β-hCG levels on day 7 in both, successful and unsuccessful single-dose MTX groups.

Get Citation

Keywords

ectopic pregnancy, methotrexate, single dose, human chorionic gonadotropin, treatment success

About this article
Title

The role of early determination of β-human chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy

Journal

Ginekologia Polska

Issue

Vol 87, No 7 (2016)

Article type

Research paper

Pages

484-487

Published online

2016-07-29

DOI

10.5603/GP.2016.0030

Pubmed

27504939

Bibliographic record

Ginekol Pol 2016;87(7):484-487.

Keywords

ectopic pregnancy
methotrexate
single dose
human chorionic gonadotropin
treatment success

Authors

Handan Çelik
Miğraci Tosun
Yüksel Işık
Bahattin Avcı

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl